Abstract 327TiP
Background
Management of platinum resistant ovarian cancer has always been challenging for oncologists. Best option in this setting is single agent chemotherapy with bevacizumab. However, due to various contraindications and financial constraints, many of them do not receive bevacizumab. Due to high expression of folate receptor alpha in high grade epithelial ovarian cancers pemetrexed could be a potential treatment option. To our knowledge there are only 2 phase II trials across the globe showing the effectiveness of pemetrexed in platinum resistant/refractory ovarian cancer and till date there is no prospective data in Indian patients with platinum resistant/refractory ovarian cancer.
Trial design
The study is a single centre, investigator-initiated, single arm phase II clinical trial designed using Simon two stage optimal design. Eligible patients are adults (age ≥18 years), with histologically confirmed high grade epithelial ovarian or primary peritoneal cancer, who have relapsed within 6 months of platinum-based chemotherapy, who are bevacizumab ineligible, with ECOG performance status of 0-2, adequate organ function, with either measurable disease with at least one target lesion for response evaluation as per RECIST 1.1 criteria or non-measurable disease with CA-125 level ≥2 times ULN measured at least 2 weeks before enrolment. Estimated sample size is 63. At least 2 out of 22 responses in stage I are expected in order to proceed to stage II and further recruitment of the patients. Baseline contrast enhanced CT scan of chest, abdomen and pelvis along with CA-125 level will be recorded. Eligible patients will receive Pemetrexed at dose of 500 mg/m2 every 21 days. Response assessment will be done after 3 cycles of chemotherapy (RECIST 1.1 will be used for measurable disease and GCIG criteria using CA-125 level will be used for non-measurable disease) and subsequent responses will be assessed every 12-16 weeks. Treatment will continue until progression, intolerable toxicity or death. Primary objective is Objective Response Rate (ORR). Secondary objectives are Progression Free survival (PFS), Overall Survival (OS), Clinical Benefit Rate (CBR), Toxicity profile and Quality of Life (QoL).
Clinical trial identification
CTRI/2022/08/044939.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract